Damon Mcknight
Australia's pharmaceutical industry is a significant sector, with a market size projected to reach $12.9 billion by 2025, experiencing a surge in demand for innovative and personalised medications. The industry is heavily regulated by the Australian government, which has resulted in a stable market, and is supported by government investment in the Pharmaceutical Benefits Scheme (PBS), which subsidises prescription medicines for residents. The country's ageing population is a key growth driver, with older age groups consuming more pharmaceutical products to manage chronic conditions. The largest market is oncology drugs, projected to have a market volume of US$1.97 billion in 2025.
Explore related products
What You'll Learn
Market size and growth
The pharmaceutical industry in Australia is a significant sector, with a market size that has been growing steadily over the years. In 2016, the industry was valued at just over $22.85 billion, and by 2020, it had surpassed $25 billion, representing a compound annual growth rate (CAGR) of 2%. This growth is expected to continue, with projections showing an estimated market size of US$10.63 billion in 2025, a further increase from the estimated US$10.16 billion in 2024. The industry is expected to grow at an annual rate of 4.98% from 2025 to 2029, resulting in a market volume of US$12.91 billion by 2029, according to some sources, or US$13.20 billion by 2028, according to others.
The pharmaceutical industry in Australia is heavily regulated by the government, which has resulted in a relatively stable market. The industry also benefits from government investment through initiatives like the Pharmaceutical Benefits Scheme (PBS), which subsidizes prescription medicines for Australian residents. This scheme has come under pressure due to rising healthcare costs and an ageing population, leading to increased scrutiny of pharmaceutical prices and a push towards greater use of generics and biosimilars. The ageing population in Australia has also resulted in a rise in demand for medications to treat chronic conditions such as diabetes, cardiovascular disease, and arthritis. This trend is expected to continue, with the government's Sixth Intergenerational Report, released in August 2023, highlighting an ageing population as a significant societal and economic shift.
The pharmaceutical market in Australia is also experiencing a surge in demand for innovative and personalized medications. This includes a growing popularity of e-pharmacies, with customers valuing the convenience and accessibility of online pharmacies. Additionally, there is a rising trend of biosimilars being accepted as a cost-effective alternative to branded biologic drugs, and a shift towards personalized medicine tailored to individual patients' genetic makeup. The largest market segment in Australia is oncology drugs, projected to have a market volume of US$1.97 billion in 2025 or US$2.01 billion in 2024, depending on the source.
The pharmaceutical industry in Australia is a knowledge-based and technology-intensive industry, attracting substantial foreign investment. Despite exports amounting to over five billion Australian dollars annually, Australia remains a net importer of pharmaceutical goods. The industry is highly competitive, with companies like AstraZeneca Holdings, Aspen Asia Pacific, and Viatris vying for market share. The industry also offers opportunities for increasing foreign direct investment (FDI) and a favorable tax environment, with incentives to reduce taxes on profits derived from the commercialization of intellectual property.
Zumiez: Shipping to Australia?
You may want to see also
Explore related products
Oncology drugs
The pharmaceutical industry in Australia is significant, with a projected revenue of US$10.63 billion in 2025 and an expected annual growth rate of 4.98% from 2025 to 2029, resulting in a market volume of US$12.91 billion by 2029. The industry is heavily regulated by the Australian government, leading to a relatively stable market. The government's Pharmaceutical Benefits Scheme (PBS) subsidizes prescription medicines for residents, while also facing pressure due to rising healthcare costs.
The oncology drugs market is a crucial segment within the Australian pharmaceutical industry. Valued at USD 250 million in 2023, it is expected to grow at a CAGR of 8.9% from 2023 to 2030, reaching USD 454 million. The market is driven by the increasing prevalence of cancer, especially in the aging population, and the demand for innovative treatments. Australia's well-established healthcare system, providing universal access to cancer treatments, also contributes to the high demand for oncology drugs.
The shift in customer preferences towards targeted therapies and immunotherapies, over traditional chemotherapy, is another significant factor influencing the oncology drugs market. These treatments offer lower toxicity, higher efficacy, and fewer side effects by targeting specific cancer cells. The approval of new drugs and therapies, along with the development of personalized medicine, further propel market growth.
Leading oncology drug companies, such as AstraZeneca, Sanofi, Novartis, Pfizer, and Bristol Myers Squibb, are investing heavily in research and development to expand their product lines and global presence. The oncology drugs market is expected to continue its growth trajectory, with a projected volume of US$3.42 billion in 2028, contributing significantly to the expansion of the Australian pharmaceutical industry.
The Australian pharmaceutical industry presents opportunities for investment, including increasing foreign direct investment (FDI) and a favorable tax environment. The industry's knowledge-intensive nature and government support through the PBS and R&D tax incentives enhance its attractiveness for investors. The market is expected to benefit from increased investment in the healthcare sector and advancements in cancer research and drug development.
Jasper's Australian Sources: A Comprehensive Guide
You may want to see also
Explore related products
Foreign investment
Australia's pharmaceutical industry has attracted substantial foreign investment. The market size of the pharmaceutical product manufacturing industry in Australia is projected to reach $12.9 billion in 2025, growing at a CAGR of 4.3% between 2019 and 2024. The industry has experienced steady growth over the past decade, with increasing demand for innovative and personalized medications. This demand is driven by several factors, including an ageing population, rising incidences of chronic diseases, and the increasing burden of diabetes.
The Australian government's heavy regulation of the industry has resulted in a relatively stable market. However, the government's Pharmaceutical Benefits Scheme (PBS), which provides subsidised prescription medicines to residents, has been under pressure due to rising healthcare costs. This has led to increased scrutiny of pharmaceutical prices and a push towards generics and biosimilars. The PBS is embedded in the country's public healthcare system and plays a crucial role in ensuring the accessibility of essential medicines.
The Australian pharmaceutical market is expected to continue growing, with a projected CAGR of 6.25% from 2025 to 2030. This growth is attributed to key strategies adopted by market leaders, increased investment, and rising research and development activities. The industry is also driven by a focus on preventive care and the development of new therapies, including vaccines, biologics, and precision medicines for complex and chronic diseases.
Sears Shipping to Australia: What You Need to Know
You may want to see also
Explore related products
Government regulation
The Australian government heavily regulates the pharmaceutical industry, resulting in a relatively stable market. The government's Pharmaceutical Benefits Scheme (PBS) subsidises prescription medicines for Australian residents. The PBS has been under pressure due to rising healthcare costs, leading to increased scrutiny of pharmaceutical prices and a push towards greater use of generics and biosimilars. The PBS is supported by government investment and the sale of medicine, with 140 separate firms listed as suppliers.
Public authority in Australia with respect to prescription drugs is shared among several agencies. The Therapeutic Goods Administration (TGA) administers product safety controls, while the Pharmaceutical Benefits Branch of the Department of Health and Ageing is responsible for access and equity arrangements. The Pharmaceutical Section of the Department of Industry, Tourism and Resources sponsors programs to assist industry development. The TGA also regulates the import, export, and manufacture of controlled substances through the Office of Drug Control, ensuring that only authorised health practitioners can prescribe medicines.
The Australian government also encourages the use of biosimilar medicines, which are as effective as the original brand of biological medicine. Biosimilars improve access to treatments for seriously ill patients and help make the PBS more sustainable through increased competition. The government supports medical research and innovation through various grant programs, including the Medical Research Future Fund, which provides funding opportunities for researchers annually.
The COVID-19 pandemic highlighted the importance of a robust healthcare system, which may lead to increased investment in the pharmaceutical industry in the future. The Australian pharmaceutical market is experiencing a surge in demand for innovative and personalised medications, with a growing trend towards e-pharmacies and cost-effective alternatives. The market is projected to reach US$10.63 billion in 2025 and is expected to grow at an annual rate of 4.98% from 2025 to 2029, resulting in a market volume of US$12.91 billion.
The Art of Boomerangs: Australian Craftsmanship
You may want to see also
Explore related products
![Easy@Home 5 Panel Urine Drug Test Kit [5 Pack] - THC/Marijuana, Cocaine, OPI/Opiates, AMP, BZO All Drugs Testing Strips in One Kit - at Home Use Screening Test with Results in 5 Mins #EDOAP-754](https://m.media-amazon.com/images/I/81pqr85M3-L._AC_UY218_.jpg)
Top pharmaceutical companies
The pharmaceutical industry in Australia is big and growing. The market is projected to reach US$10.16 billion in 2024, with a projected market volume of US$2.01 billion for oncology drugs, the largest market. By 2025, the market is expected to grow to US$10.63 billion, and by 2029, it is projected to reach US$12.91 billion.
The industry is heavily regulated by the Australian government, which has resulted in a relatively stable market. The government also provides financial support through the sale of medicine listed in the Pharmaceutical Benefits Scheme (PBS) and the R&D tax incentive. The PBS has, however, been under pressure due to rising healthcare costs. This has led to increased scrutiny of pharmaceutical prices and a push towards greater use of generics and biosimilars.
The aging population in Australia has resulted in a rise in demand for medications to treat chronic conditions such as diabetes, cardiovascular disease, and arthritis. This, along with the COVID-19 pandemic, has highlighted the importance of a robust healthcare system and is expected to lead to increased investment in the pharmaceutical industry.
Several companies are making significant strides in the Australian pharmaceutical industry. Here are some of the top pharmaceutical companies in Australia:
- Neuren Pharmaceuticals: This company develops new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood and have limited treatment options.
- Mayne Pharma: A specialty pharmaceutical company that focuses on commercialising novel pharmaceuticals to offer patients better, safer, and more accessible medicines.
- Incannex: A clinical-stage pharmaceutical development company that develops unique medicinal cannabis products and psychedelic medicine therapies for treating various conditions such as sleep apnea, traumatic brain injury, lung inflammation, rheumatoid arthritis, and more.
- Starpharma Holdings: A world leader in dendrimer technology for medical applications, focused on developing and commercialising novel therapeutic products that address significant global healthcare needs.
- Recce Pharmaceuticals: This company pioneers a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and antimicrobial resistance.
- Probiotic Limited: One of Australia's largest full-service contract manufacturers, providing marketing and distribution of prescription and over-the-counter pharmaceuticals, complementary medicines, and human nutrition products.
Political Asylum in Australia: Application Process Simplified
You may want to see also
Frequently asked questions
The size of the pharmaceutical industry in Australia is projected to reach US$10.63 billion in revenue in 2025, with a market volume of US$12.91 billion by 2029.
The pharmaceutical industry in Australia is driven by an ageing population, rising healthcare costs, and an increasing focus on preventative medicine and chronic disease management. The industry is heavily regulated by the Australian government, leading to a relatively stable market.
Some major companies in the Australian pharmaceutical industry include AstraZeneca Holdings, Aspen Asia Pacific, Viatris, Neuren Pharmaceuticals, Mayne Pharma, Incannex, and Starpharma Holdings.
The Australian pharmaceutical industry offers several investment opportunities, including increasing foreign direct investment (FDI), emerging generic drugs, and a favourable tax environment with incentives for innovation. The industry is supported by government investment in the Pharmaceutical Benefits Scheme (PBS).
